MAPK9 Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-MAPK9 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | MAPK9 |
| Clone | polyclonal |
| Host Species | Rabbit |
| Reactive Species | human, mouse |
| Isotype | n/a |
| Format | affinity purified |
| Size | 0.1 mL |
| Concentration | n/a |
| Applications | Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2. In turn, MAPK9/JNK2 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity. In response to oxidative or ribotoxic stresses, inhibits rRNA synthesis by phosphorylating and inactivating the RNA polymerase 1-spec |
| Immunogen | Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 1-424 of human MAPK9 (NP 002743.3). |
| Other Names | [JNK2; SAPK; p54a; JNK2A; JNK2B; PRKM9; JNK-55; SAPK1a; JNK2BETA; p54aSAPK; JNK2ALPHA] |
| Gene, Accession # | [MAPK9], Gene ID: 5601, NCBI: NP_001128516.1, UniProt: P45984 |
| Catalog # | MBS8544346 |
| Price | $280 |
| Order / More Info | MAPK9 Antibody from MYBIOSOURCE INC. |
| Product Specific References | n/a |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies